MusunuruK, GrandinetteSA, WangX, et al.Patient-specific in vivo gene editing to treat a rare genetic disease. N Engl J Med, 2025; 392(22):2235–2243; doi: 10.1056/NEJMoa2504747
2.
BrooksDL, WhittakerMN, SaidH, et al.A base editing strategy using mRNA-LNPs for in vivo correction of the most frequent phenylketonuria variant. HGG Adv, 2024; 5(1):100253; doi: 10.1016/j.xhgg.2023.100253
3.
GropmanAL, KomorAC. Personalized Gene Editing to Treat an Inborn Error of Metabolism. N Engl J Med, 2025; 392(22):2273–2276; doi: 10.1056/NEJMe2505721
4.
MarksP. Progress in the development of N-of-1 therapy. N Engl J Med, 2025; 392(22):2271–2272; doi: 10.1056/NEJMe2505704
5.
UrnovFD. Give Cas a chance: An actionable path to a platform for CRISPR cures. CRISPR J, 2024; 7(5):212–219; doi: 10.1089/crispr.2024.0082
